Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes.
Insulin is an effective medication for lowering hemoglobin A(1c) values and can be used for both basal and prandial coverage of hyperglycemia in Type 1 and Type 2 diabetes. Despite its effectiveness there is still reluctance by patients and physicians to add insulin into the treatment regimen for Type 2 diabetes when needed. One of the key barriers to initiating insulin therapy is the method of delivery. Insulin delivery pens are continually developed as a means to improve upon the vial and syringe and to make it easier for patients to incorporate insulin therapy into their lifestyles. The SoloSTAR pen (Sanofi-Aventis, Paris, France) was developed to make insulin delivery easier and to help eliminate barriers to the initiation of insulin therapy. In this article, we discuss the features and characteristics of SoloSTAR that overcome existing unmet needs.
Garg
Samita
S
Department of Internal Medicine, University of Colorado at Denver and Health Sciences Center, Denver, USA. satish.garg@uchsc.edu
Kelly
William Charles
WC
Garg
Satish
S
D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D013594:Syringes
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine